PepGen said EVP and R&D head Paul Streck will present the company’s ongoing myotonic dystrophy type 1 research at WMS2026 during Poster Session 4, highlighting its continued focus on DM1.
published
PepGen said EVP and R&D head Paul Streck will present the company’s ongoing myotonic dystrophy type 1 research at WMS2026 during Poster Session 4, highlighting its continued focus on DM1.
Latest documented BWB result
$APP market result
Sold the $280 10/9 Calls on $APP for $7.80
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.